Moderna

Buy Moderna shares

MODERNA NASDAQ: MRNA

Buy Moderna shares

Background of Moderna

  • Moderna Inc is an American pharmaceutical and biotechnology company focusing on vaccine technologies based on messenger RNA (mRNA).
  • Moderna Inc is based in Cambridge, Massachusetts.
  • Moderna Inc’s vaccine platform inserts synthetic nucleoside-modified messenger RNA (modRNA) into human cells using a coating of lipid nanoparticles, which then reprograms the cells to prompt immune responses.
  • Moderna Inc oversees a high value product portfolio with its only commercial product the Moderna COVID-19 vaccine, but with 24 vaccine candidates, including vaccine candidates for seasonal flu, HIV, the Nipah virus, and a second COVID-19 vaccine that will be easier to store and administer than existing vaccines.
  • Moderna Inc has a rich history that dates to 2010 when ModeRNA Therapeutics was formed to commercialise the research of stem cell biologist Derrick Rossi.
  • In 2013, Moderna Inc and AstraZeneca signed a five-year exclusive option agreement to discover, develop, and commercialize mRNA for treatments in the therapeutic areas of cardiovascular, metabolic, and renal diseases, and selected targets for cancer.
  • In 2018, Moderna Inc became a public company via the largest biotech initial public offering in history, raising $621 million.
  • Through year-end 2019, Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019, and had raised $3.2 billion in equity since 2010.[10]
  • The Moderna COVID‑19 vaccine was developed by Moderna Inc, the United States National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
  • In March 2025, Moderna Inc announced it could have a COVID-19 vaccine ready in a few months and the FDA immediately approved clinical trials for the Moderna vaccine candidate, with the company later receiving investment of $483 million from Operation Warp Speed.
  • In November 2025, it was announced that the Moderna COVID-19 vaccine candidate had shown preliminary evidence of 94% efficacy in preventing COVID-19 in a Phase III trial, after which the Moderna and Pfizer COVID-19 vaccines were approved for marketing under emergency use authorizations from the FDA and regulatory agencies in other countries.
  • Today, Moderna Inc is truly one of the most valuable biotechnology companies in the world with a market capitalization of US$ 142.33 billion recorded in July 2025.
  • In 2025 the total staff compliment for Moderna Inc was more than 1 300.
  • Moderna Inc’s executive leadership team consists of: Noubar B. Afeyan – Non-Executive Independent Chairman of the Board, Co-Founder; Stephen Hoge – President; Stephane Bancel – Chief Executive Officer, Director; and David W. Meline – Chief Financial Officer.

Moderna Shares Growth Driver

  • Moderna Inc is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells.
  • Moderna Inc’s therapeutics and vaccine development programmes span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases.
  • Moderna Inc announced its first-ever profit, which surpassed $1 billion, thanks to its sole product: the coronavirus vaccine.
  • Moderna Inc expects more than $19 billion in vaccine sales this year and reported progress on vaccine orders for next year, too.
  • Analysts are eager to hear an update regarding Moderna Inc’s investigational booster shot, since the subject has gathered a lot of attention in recent days because of the increase in variants like the highly contagious delta variant and the possibility of waning immunity in those vaccinated early in the initial vaccine rollout.
  • Currently the FDA and Centres for Disease Control and Prevention (CDC) say boosters are not needed for those who are fully vaccinated but that could change quickly if current disease trends continue.
  • Both Moderna Inc and rival Pfizer have indicated that boosters may be needed about eight months after initial vaccination, which can influence revenue considerably: 63 million people in the U.S. have received the Moderna vaccination and if each of them gets a Moderna booster, it equals more than $960 million in sales.
  • This number clearly will increase as more people get vaccinated, leave alone international sales.
  • Moderna Inc shares already have gained more than 200% this year and if the programme with billion-dollar potential stays on track, Moderna Inc stock could head considerably higher now and into the future.
  • As such, the company’s innovative and competitive portfolio has allowed it to defy the market trends surrounding the coronavirus pandemic, with performance and shares still attractive after a tumultuous 2025.

Moderna Investor Tip

  • Moderna Inc trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol MRNA. Moderna Inc forms part of both the NASDAQ-100 and S&P 500 components.
  • An analysis on Moderna Inc’s market performance and income statement indicates Revenue (ttm) of 2.73 billion, Revenue Per Share (ttm) 6.95, Quarterly Revenue Growth (yoy) 24,112.50%, Gross Profit (ttm) -574.88 Billion, EBITDA 673.11 million, Net Income Avi to Common (ttm) 597.94 million and Diluted EPS (ttm) 1.49.
  • Moderna Inc is a biotechnology company that develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, its main product being the COVID-10 vaccine.
  • Moderna Inc has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defence Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation.
  • Moderna, Inc. also collaborates with several other companies on the manufacture of COVID-19 vaccine.
  • Rival Pfizer generated $7.8 billion in coronavirus-related revenue in the second quarter and expects to deliver 2.1 billion doses and earn $33.5 billion in COVID-19 vaccine revenue in 2025, up from its prior estimate of $26 billion, which means it is likely for Moderna Inc to also benefit from the same factors that are driving its competitor’s sales and profits higher.
  • The demand for safe and effective COVID-19 vaccines is rising as new coronavirus strains emerge and case counts mount around the world.
  • Investors can expect to receive updated revenue and earnings projections from Moderna Inc when it reports its second-quarter financial results on Aug. 5.
  • Moderna Inc delivered a stable performance despite the economic impact which resulted from the global coronavirus pandemic. This stable performance can be largely owed to the company’s diverse portfolio, as well as its strong medical supplies sector which witnessed growing demand as hospitals geared up to combat the virus.
  • With sound financials and significant, consistent, and continuous growth forecasted for the remainder of 2025, shareholders who buy or sell shares can expect lucrative dividends and returns.
  • Overall, the company’s a stable performance has resulted in healthy dividends and a good share price for investors who choose to purchase shares today, securing a decent buy-in in 2025 and in the future.
  • Data from this analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.

Sector

Biotechnology

Industry

Tech Hardware and Semiconductors

Sub industry

Pharmaceuticals

Latest News

Moderna: How to buy Moderna Shares Online

Here are the steps you need to follow to buy Moderna Inc shares with utmost confidence:

  • Navigate to the AvATrade website and select ‘Register’.
  • Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
  • As soon as your account application has been reviewed and approved, you can select your trading platform from AvATrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
  • Once you have downloaded the trading platform of your choice, you can use your AvATrade live account details to log into your AvATrade account on the trading platform.
  • From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘Moderna Inc’ or ‘MRNA’ to buy/purchase shares.
  • Alternatively, you can make use of AvATrade’s online Web Trader or the AvATradeGo mobile application.

 

Trading CFDs and Stocks with AvATrade provides traders with the following benefits:

  • Leverage of up to 1:20.
  • Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
  • Indices, stocks, and commodities can all be traded form a single screen.
  • Client support is presented live in a multitude of languages.
  • Traders have exclusive access to a variety of educational tools.
  • Trades can be executed across multiple platforms.

 

More shares that can be purchased through AvATrade, can be viewed here.

FAQ

Can I buy Moderna Inc shares in South Africa?

Yes, you can.

 

How to buy Moderna Inc shares?

By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.

 

What is the current share price?

By clicking on the link provided above, you can view the real-time Moderna Inc share price on the platform.

 

Is Moderna Inc a good share to buy?

Yes, it is. Despite the growing concerns surrounding Covid-19, Moderna Inc is continuing manufacturing, sales and delivery of its products and it is forecasted to be one of the very few automotive companies to make a significant rebound post-Covid-19.

 

Can I buy Moderna Inc CFD through SA Shares?

Yes, you can.

4.6/5 - (20 votes)